Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Fabrice Bailleux"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 1, Pp 72-79 (2019)
The live-attenuated Japanese encephalitis chimeric virus vaccine JE-CV (IMOJEV®, Sanofi Pasteur) elicits a robust antibody response in children, which wanes over time. Clinical efficacy is based on a correlate of protection against JE infection defi
Externí odkaz:
https://doaj.org/article/efa34ff6b2394eb6bf09f30d73313032
Publikováno v:
BMC Medical Research Methodology, Vol 17, Iss 1, Pp 1-1 (2017)
Externí odkaz:
https://doaj.org/article/82b21c3fb1af4ccdbebc25c29fdf9dd0
Autor:
Peter B. Gilbert, Shida Shangguan, Fabrice Bailleux, Sanjay Gurunathan, Michal Juraska, Aviva Geretz, Christopher Bryant, Zoe Moodie, Shuying Sue Li, Kriengsak Limkittikul, Danaya Chansinghakul, Philip K. Ehrenberg, Wut Dulyachai, Richard G. Jarman, Nelson L. Michael, Alain Bouckenooghe, Carina Frago, Rasmi Thomas, Arunee Sabchareon, Weerawan Hattasingh
Publikováno v:
Human Immunology. 83:53-60
The recombinant, live, attenuated, tetravalent dengue vaccine CYD-TDV has shown efficacy against all four dengue serotypes. In this exploratory study (CYD59, NCT02827162), we evaluated potential associations of host human leukocyte antigen (HLA) alle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d2b3146a544202a59e85dddd275ad0
https://doi.org/10.1016/j.humimm.2021.09.006
https://doi.org/10.1016/j.humimm.2021.09.006
Publikováno v:
Statistics in Biopharmaceutical Research. 14:28-32
Traditional vaccine clinical development is an undertaking involving meticulous, multiple studies in multiple populations at risk of infection and disease over multiple years SARS-CoV-2 and COVID-19 vaccine development is following this traditional d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e62596318dd3f0a48021739bd7014d45
https://doi.org/10.1080/19466315.2021.1919197
https://doi.org/10.1080/19466315.2021.1919197
Publikováno v:
Human Vaccines & Immunotherapeutics
The live-attenuated Japanese encephalitis chimeric virus vaccine JE-CV (IMOJEV®, Sanofi Pasteur) elicits a robust antibody response in children, which wanes over time. Clinical efficacy is based on a correlate of protection against JE infection defi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2bd194b4cfe58d7192dbeb14e281893
https://doi.org/10.1080/21645515.2018.1515455
https://doi.org/10.1080/21645515.2018.1515455
Clinical safety and immunogenicity data in vaccines are commonly dichotomized into responder and nonresponder binary data. This article expands upon Fagerland, Lyndersen, and Laake to further study Newcombe’s hybrid score and Fisher’s conditional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::340c16fc0559e3030c5b2b818e78d5c1
Publikováno v:
Vaccine. 30:2510-2515
In a study conducted in a non-endemic area, a live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) was found to provide 97% seroprotection at 6 months in JE-naive adults after 1 dose, and 87% of those protected at 6 months were still
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f1bee5310e07a7f0c02bbe73fc5a55
https://doi.org/10.1016/j.vaccine.2012.02.005
https://doi.org/10.1016/j.vaccine.2012.02.005
Autor:
Ron Dagan, Helena Käyhty, Fabrice Bailleux, Orly Zamir, Tomi Wuorimaa, Mansour Yaich, Juhani Eskola
Publikováno v:
The Pediatric Infectious Disease Journal. 23:91-98
BACKGROUND To have wide global coverage of pneumococcal serotypes, the number of serotypes covered by the current 7-valent pneumococcal conjugate vaccine must be increased. We have studied the safety and immunogenicity of an 11-valent mixed carrier v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985968dcdc4383179158070dfe64a523
https://doi.org/10.1097/01.inf.0000109221.50972.53
https://doi.org/10.1097/01.inf.0000109221.50972.53
Publikováno v:
BMC Medical Research Methodology, Vol 17, Iss 1, Pp 1-1 (2017)
BMC Medical Research Methodology
BMC Medical Research Methodology
Background Immunological correlates of protection are biological markers such as disease-specific antibodies which correlate with protection against disease and which are measurable with immunological assays. It is common in vaccine research and in s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a53bcf4b0984c780c821db670dbbe2
http://link.springer.com/article/10.1186/s12874-016-0279-z
http://link.springer.com/article/10.1186/s12874-016-0279-z
Autor:
Helena Käyhty, Merja Väkeväinen, Mansour Yaich, Tomi Wuorimaa, Fabrice Bailleux, Eskola J, Raili Haikala, Ron Dagan
Publikováno v:
The Journal of Infectious Diseases. 184:1211-1215
Finnish and Israeli infants received an 11-valent mixed-carrier pneumococcal conjugate vaccine with or without aluminum adjuvant at 2, 4, 6, and 12 months of age. The relative avidity of serotype 1-, 5-, 6B-, 14-, 19F-, and 23F-specific IgG antibodie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da503de38861f3be2d5668bbcfbc7c24
https://doi.org/10.1086/323648
https://doi.org/10.1086/323648